Skip to content

Released Feb 10, 2021, after the close

10-K filed Feb 25, 2021, 56 days after period end · 0001162194-21-000013

Q4 2020 · 10-K
Revenue$44.61M+37.5% vs Q4 2019+11.9% vs Q3 2020
Net Income-$18.03MderivedN/M vs Q4 2019N/M vs Q3 2020
EPS Diluted-$0.24N/M vs Q4 2019N/M vs Q3 2020
Gross Profit$22,079,000+25.9%
Operating Incomederived-$16,904,000N/M
Operating Cash Flowderived-$3,733,000N/M
Free Cash Flowderived-$14,440,000N/M
Margins · derived
Gross margin49.5%−4.6 pt vs Q4 2019
Operating margin-37.9%−9.6 pt vs Q4 2019
Net margin-40.4%−1.3 pt vs Q4 2019

What the release said

The release

Same quarter

MetricQ4 2020Q4 2019Q4 2018Q4 2017
Revenue$44.61M$32.44M$32.33M$27.75M
Net Income-$18.03M-$12.69M-$14.78M-$10.46M
EPS Diluted-$0.24-$0.18-$0.36-$0.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR